Overview

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Status:
Terminated

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer. Time to tumor progression, objective response rate, time to confirmed response rate, duration of confirmed response rate, time to treatment failure, and CEA response will be assessed.

Phase:

Phase 2

Details

Lead Sponsor:

Peter Kozuch

Collaborators:

Genentech, Inc.
Hoffmann-La Roche

Treatments:

Capecitabine
Erlotinib Hydrochloride